Boston Scientific (BSX) raised its financial guidance for 2025 after the medical device manufacturer's first-quarter results exceeded Wall Street's projections, as the company named a new chief financial officer.

Adjusted per-share earnings are now expected between $2.87 and $2.94 this year, up from the company's previous view of $2.80 to $2.87. The consensus on FactSet is for non-GAAP EPS to rise to $2.86 from last year's $2.51.

The company now anticipates full-year revenue growing 15% to 17%, faster than its previous outlook of 12.5% to 14.5%. Analysts are projecting sales to increase to $19.2 billion from $16.75 billion in 2024. Boston Scientific's stock advanced 5.4% intraday Wednesday.

The outlook takes into account a roughly $200 million impact from tariffs, company executives told analysts at an earnings call.

"We expect to fully offset this $200 million unanticipated headwind through our full-year organic sales guidance raise, targeted discretionary spend reductions and a $0.01 (foreign exchange) benefit," CFO Daniel Brennan said, according to a FactSet transcript.

Most of the tariffs' impact are likely to be seen in the second half of the year, according to Brennan, who is retiring after a nearly 30-year career at Boston Scientific. The company promoted Jon Monson to CFO, effective June 30, from his current role as senior vice president of investor relations. Starting July, Brennan is expected to remain with Boston Scientific as a senior adviser through early October 2025.

For the March quarter, adjusted EPS rose to $0.75 from $0.56 a year earlier and exceeded analysts' forecast of $0.67. Sales jumped 21% to $4.66 billion, above the Street's $4.57 billion view.

By segment, MedSurg sales increased nearly 12% to $1.58 billion while cardiovascular climbed 26% to $3.09 billion.

For the June quarter, Boston Scientific expects adjusted EPS of $0.71 to $0.73 on revenue growth of about 17.5% to 19.5%. Analysts are looking for $0.71 and $4.79 billion, respectively.